论文部分内容阅读
目的:参苓白术散加减联合恩替卡韦治疗慢性乙型肝炎对HBs Ag定量的影响。方法:选择70例慢性乙型肝炎采用恩替卡韦分散片抗病毒患者,随机分为治疗组35例,对照组35例。治疗组在基本治疗基础上,给予参苓白术散加减治疗。24周后进行疗效评价。随访24周。结果:治疗组与对照组相比,丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)、血清总胆红素(TBIL)、直接胆红素(DBIL)、碱性磷酸酶(ALP)无显著性差异,治疗24周、随访24周HBs Ag定量变化有显著差异。结论:参苓白术散加减联合恩替卡韦治疗慢性乙型肝炎,HBs Ag定量有较明显下降。提示益气健脾中药对慢性乙肝患者治疗有重要意义,值得进一步研究。
Objective: To investigate the effect of Shenling Baizhu San combined with entecavir in the treatment of chronic hepatitis B on the quantification of HBs Ag. Methods: Seventy patients with chronic hepatitis B who were treated with entecavir dispersible tablet antiviral were randomly divided into treatment group (35 cases) and control group (35 cases). Treatment group based on the basic treatment, given Shenling Baizhu addition and subtraction treatment. Efficacy evaluation after 24 weeks. Followed up for 24 weeks. Results: Compared with the control group, ALT, AST, GGT, TBIL ), Direct bilirubin (DBIL), alkaline phosphatase (ALP) no significant difference in the treatment of 24 weeks, 24 weeks follow-up quantitative changes in HBsAg significant differences. Conclusion: Shenling Baizhu San combined with entecavir treatment of chronic hepatitis B, HBsAg quantitative decreased significantly. Prompt Yiqi spleen Chinese medicine treatment of chronic hepatitis B patients is of great significance, it is worth further study.